Methamphetamine toxicity and its implications during HIV-1 infection

Journal of NeuroVirology

Volumn 17, Issue 5, 2011, Pages 401-415

  Silverstein, Peter S ^a   Shah, Ankit ^a   Gupte, Raeesa ^a   Liu, Xun ^a   Piepho, Robert W ^a   Kumar, Santosh ^a   Kumar, Anil ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

CNS; Dopamine; HIV 1; Immune system; Methamphetamine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFONELIC ACID; ANTIVIRUS AGENT; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; GLYCOPROTEIN GP 120; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; METHAMPHETAMINE; MUSCARINIC RECEPTOR; PEROXIREDOXIN; RACLOPRIDE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VESICULAR MONOAMINE TRANSPORTER 2;

ANTIGEN PRESENTATION; APOPTOSIS; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG DOSE ESCALATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTHERMIA; LIPID PEROXIDATION; MICROTUBULE ASSEMBLY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; DOPAMINE; DOPAMINE AGENTS; FEVER; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHAMPHETAMINE; OXIDATIVE STRESS; STREET DRUGS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84862908023     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-011-0043-4     Document Type: Review

References (136)

1. Acikgoz O, Gonenc S, Kayatekin BM, Uysal N, Pekcetin C, Semin I, Gure A (1998) Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res 813:200-202 (Pubitemid 29012537)
2. Amenta F, Bronzetti E, Felici L, Ricci A, Tayebati SK (1999) Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 19:151-159 (Pubitemid 29443882)
3. Angulo JA, Angulo N, Yu J (2004) Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum. Ann N Y Acad Sci 1025:171-180 (Pubitemid 39643860)
4. Anlauf M, Schafer MK, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, Horny HP, Parwaresch R, Hartschuh W, Eiden LE, Kloppel G, Weihe E (2006) Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. J Histochem Cytochem 54:201-213 (Pubitemid 43201641)
5. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799 (Pubitemid 350059308)
6. Banerjee A, Zhang X, Manda KR, Banks WA, Ercal N (2010) HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med 48:1388-1398
7. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8:67-71 (Pubitemid 24094090)
8. Brown PL, Kiyatkin EA (2005) Fatal intra-brain heat accumulation induced by meth-amphetamine at normothermic conditions in rats. Int J Neuroprotect Neuroregeneration 1:86-90
9. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302:497-501 (Pubitemid 34787211)
10. Brown PL, Wise RA, Kiyatkin EA (2003) Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci 23:3924-3929 (Pubitemid 36958498)
11. Buchacz K, McFarland W, Kellogg TA, Loeb L, Holmberg SD, Dilley J, Klausner JD (2005) Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 19:1423-1424 (Pubitemid 41800679)
12. Cadet JL, Krasnova IN (2007) Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation. Neurotox Res 12:181-204
13. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein C (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 62:380-383
14. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003) HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984:133-142 (Pubitemid 36976802)
15. Chang L, Ernst T, Speck O, Grob CS (2005) Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162:361-369 (Pubitemid 40216218)
16. Chen HM, Lee YC, Huang CL, Liu HK, Liao WC, Lai WL, Lin YR, Huang NK (2007) Methamphetamine downregulates peroxiredoxins in rat pheochromocytoma cells. Biochem Biophys Res Commun 354:96-101
17. Chung YA, Peterson BS, Yoon SJ, Cho SN, Chai S, Jeong J, Kim DJ (2010) In vivo evidence for long-term CNS toxicity, associated with chronic binge use of methamphetamine. Drug Alcohol Depend 111:155-160
18. Clifford DB (2008) HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 16:94-98
19. Conant K, St Hillaire C, Anderson C, Galey D, Wang J, Nath A (2004) Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. J Neurovirol 10:21-28 (Pubitemid 38325106)
20. Cubells JF, Rayport S, Rajendran G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14:2260-2271 (Pubitemid 24108131)
21. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22 (Pubitemid 32763126)
22. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, Tyndall M, Wiessing L, Wodak A, Howard J (2010) Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy 21:347-358
23. Dluzen DE, McDermott JL, Darvesh AS (2010) Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity. Neuroscience 167:985-993
24. Eyerman DJ, Yamamoto BK (2005) Lobeline attenuates methamphetamine- induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312:160-169 (Pubitemid 40096465)
25. Fleckenstein AE, Volz TJ, Hanson GR (2009) Psychostimulantinduced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56 (Suppl 1):133-138
26. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M (2002) Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med 2:71-85 (Pubitemid 37012511)
27. Flora G, Lee YW, Nath A, Hennig B, Maragos W, Toborek M (2003) Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol 179:60-70 (Pubitemid 36062619)
28. Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273-279 (Pubitemid 27451998)
29. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18:4861-4869 (Pubitemid 28285395)
30. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431 (Pubitemid 29162392)
31. Garcia de Yebenes J, Yebenes J, Mena MA (2000) Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease. Neurotox Res 2:115-137
32. Genc K, Genc S, Kizildag S, Sonmez U, Yilmaz O, Tugyan K, Ergur B, Sonmez A, Buldan Z (2003) Methamphetamine induces oligodendroglial cell death in vitro. Brain Res 982:125-130 (Pubitemid 37288805)
33. Gendelman HE, Meltzer MS (1989) Mononuclear phagocytes and the human immunodeficiency virus. Curr Opin Immunol 2:414-419 (Pubitemid 20185024)
34. Gibb JW, Kogan FJ (1979) Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol 310:185-187 (Pubitemid 10179569)
35. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA (2010) Psychopathology in methamphetaminedependent adults 3 years after treatment. Drug Alcohol Rev 29:12-20
36. Glass JD, Wesselingh SL, Selnes OA, McArthur JC (1993) Clinicalneuropathologic correlation in HIV-associated dementia. Neurology 43:2230-2237
37. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-160 (Pubitemid 32946652)
38. Goncalves J, Martins T, Ferreira R, Milhazes N, Borges F, Ribeiro CF, Malva JO, Macedo TR, Silva AP (2008) Methamphetamineinduced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci 1139:103-111
39. Gonzales R, Ang A, Marinelli-Casey P, Glik DC, Iguchi MY, Rawson RA (2009) Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J Subst Abuse Treat 37:353-361
40. Gonzales R, Mooney L, Rawson RA (2010) The methamphetamine problem in the United States. Annu Rev Public Health 31:385-398
41. Gorbach PM, Drumright LN, Javanbakht M, Pond SL, Woelk CH, Daar ES, Little SJ (2008) Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr 47:639-643 (Pubitemid 351442022)
42. Hogan KA, Staal RG, Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-2220 (Pubitemid 30217681)
43. Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257-262 (Pubitemid 10049032)
44. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 99:376-384 (Pubitemid 30179576)
45. Iwazaki T, McGregor IS, Matsumoto I (2006) Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res 1097:19-25 (Pubitemid 44041284)
46. Iyo M, Sekine Y, Mori N (2004) Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci 1025:288-295 (Pubitemid 39643874)
47. Jayanthi S, Ladenheim B, Cadet JL (1998) Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci 844:92-102 (Pubitemid 28367798)
48. Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, Cai NS, Cadet JL (2005) Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamineinduced neuronal apoptosis. Proc Natl Acad Sci U S A 102:868-873 (Pubitemid 40282757)
49. Kanthasamy A, Anantharam V, Ali SF, Kanthasamy AG (2006) Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death. Ann N YAcad Sci 1074:234-244 (Pubitemid 44532827)
50. Kiyatkin EA (2005) Brain hyperthermia as physiological and pathological phenomena. Brain Res Brain Res Rev 50:27-56 (Pubitemid 41607514)
51. Kiyatkin EA (2010) Brain temperature homeostasis: physiological fluctuations and pathological shifts. Front Biosci 15:73-92
52. Kiyatkin EA, Sharma HS (2011) Expression of heat shock protein (HSP 72 kDa) during acute methamphetamine intoxication depends on brain hyperthermia: neurotoxicity or neuroprotection? J Neural Transm 118:47-60
53. Kiyatkin EA, Brown PL, Sharma HS (2007) Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci 26:1242-1253 (Pubitemid 47346759)
54. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60:379-407
55. Kuhn DM, Francescutti-Verbeem DM, Thomas DM (2008) Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann N Y Acad Sci 1139:118-126
56. Kuperman DI, Freyaldenhoven TE, Schmued LC, Ali SF (1997) Methamphetamine-induced hyperthermia in mice: examination of dopamine depletion and heat-shock protein induction. Brain Res 771:221-227 (Pubitemid 27492100)
57. La Gasse LL, Wouldes T, Newman E, Smith LM, Shah RZ, Derauf C, Huestis MA, Arria AM, Della Grotta S, Wilcox T, Lester BM (2011) Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol 33:166-175
58. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ, Marcotte TD, Masliah E (2003) Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 34:467-474 (Pubitemid 37500470)
59. Langford D, Grigorian A, Hurford R, Adame A, Crews L, Masliah E (2004) The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol 10:327-337 (Pubitemid 40109620)
60. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951-8960 (Pubitemid 35379065)
61. La Voie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484-1491 (Pubitemid 29088929)
62. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ (2008) Methamphetamine enhances HIV infection of macrophages. Am J Pathol 172:1617-1624 (Pubitemid 351793354)
63. Liu X, Chang L, Vigorito M, Kass M, Li H, Chang SL (2009) Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J Neuroimmune Pharmacol 4:309-316
64. Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SN, Henriksen SJ, Fox HS (2005) Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30:350-359 (Pubitemid 40129486)
65. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A (1995) Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 37:373-380
66. Mahajan SD, Hu Z, Reynolds JL, Aalinkeel R, Schwartz SA, Nair MP (2006) Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol Diagn Ther 10:257-269 (Pubitemid 44223240)
67. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, Qi M, Toh J, Xu G, Prasad PN, Schwartz SA (2008) Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 1203:133-148
68. Mao CV, Hori E, Maior RS, Ono T, Nishijo H (2008) A primate model of schizophrenia using chronic PCP treatment. Rev Neurosci 19:83-89
69. Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A, Cass WA (2002) Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83:955-963 (Pubitemid 35316046)
70. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS (2010) Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 177:355-361
71. Marek GJ, Vosmer G, Seiden LS (1990) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 513:274-279 (Pubitemid 20132265)
72. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP et al (1993) Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43:2245-2252 (Pubitemid 23346956)
73. Melega WP, Lacan G, Harvey DC, Way BM (2007) Methamphetamine increases basal ganglia iron to levels observed in aging. Neuroreport 18:1741-1745 (Pubitemid 47549145)
74. Melega WP, Jorgensen MJ, Lacan G, Way BM, Pham J, Morton G, Cho AK, Fairbanks LA (2008) Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. Neuropsychopharmacology 33:1441-1452 (Pubitemid 351521710)
75. Meltzer MS, Gendelman HE (1992) Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol 181:239-263
76. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE (1990) Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 8:169-194 (Pubitemid 20135625)
77. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20:571-573 (Pubitemid 46671253)
78. Munch G, Raether A, Schoffel E, Illes P (1991) Postsynaptic dopamine DA1-and DA2-receptors in jejunal arteries of rabbits. J Cardiovasc Pharmacol 18:468-471
79. Nair MP, Saiyed ZM (2010) Effect of methamphetamine on expression of HIV coreceptors and CC-chemokines by dendritic cells. Life Sci 88:987-994
80. Nair MP, Mahajan S, Sykes D, Bapardekar MV, Reynolds JL (2006) Methamphetamine modulates DC-SIGN expression by mature dendritic cells. J Neuroimmune Pharmacol 1:296-304 (Pubitemid 44244134)
81. Narita M, Miyatake M, Shibasaki M, Tsuda M, Koizumi S, Yajima Y, Inoue K, Suzuki T (2005) Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J Neurochem 93:1383-1392 (Pubitemid 40853261)
82. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M (2000) Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14:222-227
83. Navia BA, Cho ES, Petito CK, Price RW (1986a) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19:525-535 (Pubitemid 16085186)
84. Navia BA, Jordan BD, Price RW (1986b) The AIDS dementia complex: I. Clinical features. Ann Neurol 19:517-524 (Pubitemid 16085185)
85. Newton TF, Kalechstein AD, Hardy DJ, Cook IA, Nestor L, Ling W, Leuchter AF (2004) Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol 115:194-198 (Pubitemid 38045614)
86. Office of Applied Studies S (2007) Methamphetamine Abuse. The NSDUH Report
87. Olsen NV (1998) Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Dan Med Bull 45:282-297 (Pubitemid 28313538)
88. Ozono R, O'Connell DP, Wang ZQ, Moore AF, Sanada H, Felder RA, Carey RM (1997) Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension 30:725-729 (Pubitemid 27444263)
89. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA (2002) Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetaminedependent subjects. Neuropsychopharmacology 26:53-63 (Pubitemid 34075276)
90. Pendyala G, Trauger SA, Siuzdak G, Fox HS (2011) Short communication: quantitative proteomic plasma profiling reveals activation of host defense to oxidative stress in chronic SIV and methamphetamine comorbidity. AIDS Res Hum Retroviruses 27:179-182
91. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G, Colao A, Lamberts SW, Hofland LJ (2004) Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 89:4493-4502 (Pubitemid 39244461)
92. Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, Dykstra H, Weksler BB, Romero IA, Couraud PO, Persidsky Y (2009) Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 29:1933-1945
93. Rawson RA, Gonzales R, Brethen P (2002) Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 23:145-150 (Pubitemid 36151695)
94. Reiner BC, Keblesh JP, Xiong H (2009) Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol 1:162-179
95. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991) Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82:39-44
96. Reynolds JL, Mahajan SD, Sykes DE, Schwartz SA, Nair MP (2007) Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC). Biochim Biophys Acta 1774:433-442 (Pubitemid 46498837)
97. Reynolds JL, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Agosto-Mujica A, Hsiao CB, Schwartz SA (2009) Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse. J Clin Immunol 29:646-656
98. Ricci A, Amenta F (1994) Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 53:1-7
99. Ricci A, Bronzetti E, Felici L, Tayebati SK, Amenta F (1997) Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 229:130-134 (Pubitemid 27306838)
100. Ricci A, Bronzetti E, Felici L, Greco S, Amenta F (1998) Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J Neuroimmunol 92:191-195 (Pubitemid 29016004)
101. Ricci A, Bronzetti E, Mignini F, Tayebati SK, Zaccheo D, Amenta F (1999) Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96:234-240 (Pubitemid 29234498)
102. Riddle EL, Fleckenstein AE, Hanson GR (2006) Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J 8:E413-E418 (Pubitemid 43964450)
103. Roberts AJ, Maung R, Sejbuk NE, Ake C, Kaul M (2010) Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J Neurosci Methods 186:222-225
104. Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E (1999) Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system. Nucleic Acids Res 27:3291-3299 (Pubitemid 29381322)
105. Romero CA, Bustamante DA, Zapata-Torres G, Goiny M, Cassels B, Herrera-Marschitz M (2006) Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats. Neurotox Res 10:11-22
106. Roussotte F, Soderberg L, Sowell E (2010) Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging. Neuropsychol Rev 20:376-397
107. Ruffolo RR Jr, Messick K (1985) Effects of dopamine, (+/-)-dobutamine and the (+) - and (-)-enantiomers of dobutamine on cardiac function in pithed rats. J Pharmacol Exp Ther 235:558-565 (Pubitemid 16210715)
108. Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA, Butler PC (2008) Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 39:543-551
109. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 304:1181-1187 (Pubitemid 36254431)
110. Schmidt CJ, Gibb JW (1985) Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur J Pharmacol 109:73-80 (Pubitemid 15134014)
111. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544 (Pubitemid 15019746)
112. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, McCutchan JA, Patterson TL, Grant I (2005) Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 11:356-364 (Pubitemid 41614515)
113. Sharma HS, Kiyatkin EA (2009) Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat 37:18-32
114. Shoptaw S, Reback CJ (2007) Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 102 (Suppl 1):130-135 (Pubitemid 46328213)
115. Siegel JA, Craytor MJ, Raber J (2010) Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice. Behav Pharmacol 21:602-614
116. Siegel JA, Park BS, Raber J (2011) Long-term effects of neonatal methamphetamine exposure on cognitive function in adolescent mice. Behav Brain Res 219:159-164
117. Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Fallone M, Liu J, Lester BM (2008) Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol 30:20-28
118. Sonsalla PK, Gibb JW, Hanson GR (1986) Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 238:932-937 (Pubitemid 16033231)
119. Sriram K, Miller DB, O'Callaghan JP (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96:706-718
120. Stephans SE, Yamamoto BK (1994) Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17:203-209 (Pubitemid 24204347)
121. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433 (Pubitemid 40834286)
122. Talloczy Z, Martinez J, Joset D, Ray Y, Gacser A, Toussi S, Mizushima N, Nosanchuk JD, Goldstein H, Loike J, Sulzer D, Santambrogio L (2008) Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog 4:e28
123. Tang Y, Nee AC, Lu A, Ran R, Sharp FR (2003) Blood genomic expression profile for neuronal injury. J Cereb Blood Flow Metab 23:310-319 (Pubitemid 36307575)
124. Theodore S, Cass WA, Maragos WF (2006a) Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol 199:490-498 (Pubitemid 43928975)
125. Theodore S, Cass WA, Nath A, Steiner J, Young K, Maragos WF (2006b) Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiol Dis 23:663-668 (Pubitemid 44234103)
126. Thomas SA (2004) Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 10:1313-1324 (Pubitemid 38568084)
127. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM (2004a) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367:349-354 (Pubitemid 39178611)
128. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004b) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1-7 (Pubitemid 39287777)
129. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028-6036 (Pubitemid 38859399)
130. Toussi SS, Joseph A, Zheng JH, Dutta M, Santambrogio L, Goldstein H (2009) Short communication: methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 25:1117-1121
131. Turchan J, Anderson C, Hauser KF, Sun Q, Zhang J, Liu Y, Wise PM, Kruman I, Maragos W, Mattson MP, Booze R, Nath A (2001) Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2:3
132. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160 (Pubitemid 10159505)
133. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703 (Pubitemid 26191961)
134. Witkovsky P (2004) Dopamine and retinal function. Doc Ophthalmol 108:17-40 (Pubitemid 38461014)
135. Xu W, Zhu JP, Angulo JA (2005) Induction of striatal pre-and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 58:110-121 (Pubitemid 41443747)
136. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M (2004) Psychiatric symptoms in methamphetamine users. Am J Addict 13:181-190 (Pubitemid 38585698)